The Food and Drug Administration today issued draft guidance describing the premarket studies that manufacturers should conduct for blood glucose monitoring systems intended for use in professional health care settings. Based on feedback from the clinical community, the guidance recommends that manufacturers ensure the studies are designed to support a Clinical Laboratory Improvement Amendments waiver for the device. A CLIA waiver allows hospitals to use the device at the point of care. Historically, FDA has not distinguished between requirements for blood glucose monitoring systems used in hospitals and other health care settings and over-the-counter meters used for self-monitoring, which are automatically waived under CLIA. FDA will accept comments on the draft guidance for 90 days after its publication in the Federal Register. 
 

Related News Articles

Headline
The Joint Commission yesterday recommended that health care organizations review cleaning and disinfection instructions for tonometers and other ophthalmology…
Headline
The Food and Drug Administration last week alerted health care providers and patients that batteries in certain Medtronic implantable pacemakers and cardiac…
Headline
The Food and Drug Administration today proposed reclassifying surgical staplers for internal use as moderate-risk rather than low-risk medical devices.
Headline
The Food and Drug Administration today ordered manufacturers to immediately stop selling and distributing surgical mesh products for transvaginal repair of…
Headline
Updated preliminary results from studies to better understand how duodenoscopes are reprocessed in real-world settings continue to show higher than expected…
Headline
The Food and Drug Administration Friday warned physicians and patients who use medical devices to monitor levels of the blood thinner warfarin that certain…